Immuneering Corporation
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $342.9M
- Price
- $5.30
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.95%
- Volume
- 445.7K
About
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Quick stats
Shares outstanding64.7M
Computed float55.9M
Float / shares86.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001790340
Websitehttps://immuneering.com
AI Summary
AI-generated1/21
majorbullishearnings
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
Immuneering reported Q2 net loss of $17.3 million ($0.27 per share) with cash, equivalents and marketable securities of $182.7 million, which management expects to fund operations into 2029.
The company initiated dosing in its pivotal Phase 3 MAPKeeper 301 trial evaluating atebimetinib in first-line pancreatic cancer, following Phase 2a data showing a median overall survival of 17.3 months in 55 patients.
Additionally, Immuneering appointed Andrew Gengos as Chief Financial Officer and published peer-reviewed data in Cancer Research supporting atebimetinib’s mechanism of action.